← Back to screener

Axsome Therapeutics, Inc. AXSM

Rank #2498 · Nasdaq · $7.4B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
12.4
P/E
-31.1
P/B
67.84
ROE
-218.4%
Op. Margin
-85.7%
Debt Ratio
467%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -31.1x, P/B 67.84x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -218.4%. Ranks in the top 93% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 467%. Ranks in the top 79% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 440.8% year over year. Ranks in the top 1% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2016–$-0.0B$-0.0B$-0.0B–-130
2017–$-0.0B$-0.0B$-0.0B–-520
2018–$-0.0B$-0.0B$0.0B–41
2019–$-0.0B$-0.0B$0.0B–67
2020–$-0.0B$-0.0B$0.0B–250
2021–$-0.1B$-0.1B$0.0B–7713
2022$0.0B$-0.1B$-0.1B$0.2B–40
2023$0.1B$-0.1B$-0.1B$0.1B-249.2195
2024$0.1B$-0.2B$-0.2B$0.0B-359.32541
2025$0.3B$-0.2B$-0.2B$0.1B-85.7467

← See the full screener